Skip to main content
. 2024 Dec 12;37:13518. doi: 10.3389/ti.2024.13518

TABLE 2.

Clinical presentation of microsporidiosis and laboratory characteristics at diagnosis.

All patients (n = 154) MIT (n = 64) Fumagillin (n = 54) Nitazoxanide (n = 36) p
Symptoms
 Diarrhea 154 (100) 64 (100) 54 (100) 36 (100) NA
 Fever (>38.5°C) 8 (5.2) 5 (7.8) 1 (1.9) 2 (5.6) 0.41
 Nausea/vomiting 58 (37.7) 24 (37.5) 18 (33.3) 16 (44.4) 0.57
 Asthenia 32 (20.8) 15 (23.4) 10 (18.5) 7 (19.4) 0.79
 Abdominal pain 31 (20.1) 16 (25.0) 5 (9.3) 10 (27.8) 0.045
 Weight loss 83 (53.9) 29 (45.3) 33 (61.1) 21 (58.3) 0.19
Weight loss (%) (n = 75) 8 [5; 12] 7 [5; 13] 9 [5; 11] 6 [5; 11] 0.71
Hospitalization rate 127 (82.5) 47 (73.4) 50 (92.6) 30 (83.3) 0.02
Serum creatinine (µmol/L) (n = 150) 187 [124; 293] (43; 838) 182 [136; 285] (85; 653) 191 [129; 278] (43; 838) 216 [118; 311] (85; 676) 0.88
Renal failure 55/100 (55.0) 27/49 (55.1) 14/23 (60.9) 14/28 (50.0) 0.74
AKIN stage 0.22
 1 21/55 (38.2) 14/27 (51.9) 3/14 (21.4) 4/14 (28.6)
 2 14/55 (25.4) 7/27 (25.9) 4/14 (28.6) 3/14 (21.4)
 3 20/55 (36.4) 6/27 (22.2) 7/14 (50.0) 7/14 (50.0)
CRP (mg/L) (n = 115) 4 [1; 11] 3 [1; 11] 5 [2; 15] 3 [1; 8] 0.31
Hemoglobin (g/dL) (n = 150) 11.6 [10.1; 12.9] 11.4 [10.0; 12.4] 11.7 [10.3; 13.4] 11.9 [10.1; 12.9] 0.87
Platelets (G/L) (n = 133) 226 [169; 268] 236 [168; 279] 219 [165; 264] 217 [173; 263] 0.96
PNN (G/L) (n = 133) 4.7 [3.3; 6.6] 4.7 [3.1; 7.1] 5.3 [3.3; 8.1] 4.5 [3.3; 5.8] 0.33
Lymphocyte (G/L) (n = 130) 1.08 [0.64; 1.60] 1.19 [0.77; 1.82] 1.10 [0.64; 1.81] 1.01 [0.51; 1.30] 0.08

Data are presented as number of patients (percentages), or median [25th; 75th percentiles] (range). Comparisons between groups were made with Chi-squared test or Fisher’s exact test for categorical data, and with Kruskal-Wallis test for quantitative data. In the first column, “n” is the number of available data when there is missing data. AKIN: acute kidney injury network (score 3 is more serious than score 1); CRP: C-reactive protein; MIT: modification of immunosuppressive treatment; NA: not applicable; PNN: polynuclear neutrophil.